Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725555 | 0.91 | HPGD (0.36) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL23251413 | 0.85 | HPGD (0.35) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL21725533 | 0.81 | HPGD (0.35) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL21725532 | 0.80 | HPGD (0.37) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL21725549 | 0.79 | PDE10A (0.39) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL22871232 | 0.75 | HPGD (0.39) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL21725548 | 0.74 | PDE10A (0.40) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL21725568 | 0.72 | HPGD (0.38) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL21859719 | 0.71 | HPGD (0.37) | HPGDKDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL21725505 | 0.70 | CRHR1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | HPGD 1592/4885KDM4E 4387/4885MEN1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.